A Trial of Episil® Oral Liquid in Cancer Patients Suffering From Chemotherapy- and/or Radiation-induced Oral Mucositis
This is a randomized, multi-center, single-use, active-controlled, two-stage open study of episil®. The purpose of this study is to assess the local analgesic effect of episil® in cancer patients suffering from chemotherapy- and/or radiation-induced oral mucositis, which will provide scientific and reliable clinical data in the product registration in China.
Chemotherapy- and/or Radiation-induced Oral Mucositis
DEVICE: episil®|DEVICE: Kang Su
Area under the curve (AUC) of pain score of oral mucositis, Oral mucosal pain is assessed by a numerical score (0-10 Likert-pain scale)., During 6 hours after a single use of investigational medical device
Pain intensity decrease inside the oral cavity, Oral mucosal pain is assessed by a numerical score (0-10 Likert-pain scale)., During 6 hours after a single use of investigational medical device|Peak pain intensity difference inside the oral cavity, Oral mucosal pain is assessed by a numerical score (0-10 Likert-pain scale)., During 6 hours after a single use of investigational medical device|Incidence of adverse events, 2 days
This is a randomized, multi-center, single-use, active-controlled, two-stage open study of episil®. The purpose of this study is to assess the local analgesic effect of episil® in cancer patients suffering from chemotherapy- and/or radiation-induced oral mucositis, which will provide scientific and reliable clinical data in the product registration in China.